Business Wire

Fabasoft Listed in the Independent “Now Tech: Content Platforms, Q1 2021” Report

Share

Fabasoft, a leading European provider of cloud solutions, was invited by Forrester to take part in an independent overview of “Content Platforms” (“The latest stage of evolution in the market traditionally known as Enterprise Content Management Systems”).

Research and advisory firm Forrester Research Inc. overviewed 38 top cloud content platforms based on platform capabilities, vertical focus, and size.

One of the key takeaways according to the authors of the “Now Tech: Content Platforms, Q1 2021” analysis* indicates that “…small and midsize vendors may offer a better range of content services and expertise in specific vertical markets.” Yet the study’s authors also offer the following words of caution: “Be wary of ‘cloudwashing’ when older technologies are hosted but branded as cloud.”

The functionality of Fabasoft Business Process Cloud as a multi-client cloud content platform covers categories addressed in the study such as “Collaborative Content Services” and “Transactional Content Services and Multitenant Cloud Content Platforms.”

Download now: Now Tech: Content Platforms, Q1 2021

“We believe being listed in the report as a native cloud provider with three of the four primary functionality segments attests to the capabilities and performance of the Fabasoft Business Process Cloud,” remarks a delighted Andreas Dangl, Business Unit Executive Cloud and digitalization expert at Fabasoft.

“With its process-driven cloud platform, Fabasoft specializes in document-centric business workflows for manufacturing, financial services, as well as architecture, engineering, and construction. Among our strengths is efficient ‘low-code’ or ‘no-code’ customizing – in other words, tailoring our products to customer requirements without the need for elaborate programming. The broad range of standard interfaces also makes it easier to connect to existing IT systems,” explains Dangl.

Forrester Now Tech is an independent and objective overview of providers focusing on a specific IT solution area.

Download now: Now Tech: Content Platforms, Q1 2021

*Forrester Now Tech: Content Platforms, Q1 2021, Cheryl McKinnon with Daniel Hong, Hailey Colin, and Sam Bartlett.

Using the Fabasoft Business Process Cloud, companies can shape their business processes and work with digital content across organizations, IT infrastructures, and countries. Fabasoft Business Process Cloud’s out-of-the-box solutions and scalable applications empower organizations to bring the focus back to their customers as they move their digital transformation forward. Companies in the industrial sector appreciate the platform’s advantages, particularly when it comes to handling major projects and implementing processes in documentation and product management. Functionalities such as workflow automation and modeling, well-defined authorization and role models, transparent versioning, automatic synchronization, and mobile use facilitate collaboration and ensure seamless transparency.

About Fabasoft

Fabasoft is among the leading software product companies and cloud service providers in Europe for digital document management as well as electronic document, process, and records management. For more than three decades, numerous prominent private enterprises and public sector organizations have placed their trust in Fabasoft’s long-standing quality and experience.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fabasoft
Ulrike Kogler
Tel.: +43/732/606162-0
E-mail: ulrike.kogler@fabasoft.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye